Cytox CEO, Dr. Richard Pither, Talks About genoSCORE™-ACT Genetic Risk Test for Alzheimer's Disease on the UK's Only Dementia-Focussed Radio Show – ‘The 'D' Word With Pete Hill'
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of the first, physician use only, polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
Cytox publishes research showing its genoSCORE-LAB test can predict the risk of cognitive decline due to Alzheimer’s disease without invasive procedures
Cardiff University and Cytox to present further results on the implementation of SNPfitR analytical platform in identifying individuals for Alzheimer’s clinical trials at AD/PD conference in Lisbon
Cytox to present research on polygenic risk score application to stratification of risk for Alzheimer’s Disease at 13th International Conference on Genomics in Shenzhen, China.
Cytox, Cardiff University and University of Birmingham to present research on application of polygenic risk score (PRS) analysis to stratification of subjects for clinical trials in Alzheimer’s disease in carriers and non-carriers of the ApoE4 risk allele
Cardiff University and Cytox to present research showing polygenic risk score approach predicts Alzheimer’s Disease and mild cognitive impairment better than APOE in ADNI dataset